PF-06342674

N/A

Report date: 2023/07/26 17:53:15

Base Information

Drug NamePF-06342674
Drug Alias NameRN-168PF-6342674PF-06342674ZB-168
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-7 receptor subunit alpha inhibitorsThymic stromal lymphopoietin inhibitors
TargetsInterleukin-7 receptor subunit alphaThymic stromal lymphopoietin
Therapy Area/IndicationsDiabetes Mellitus, Type 1Multiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesZura Bio LtdBenaroya Research Institute
Inactive CompaniesPfizer Inc
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A